title: Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
abstract: OBJECTIVE
  The purpose of this study was to examine the behavioural and cognitive effects of selegiline in a group of moderately behaviourally disturbed AD patients.
  
  
  METHODS
  This was a 14-week randomized double-blind placebo-controlled study of selegiline (10 mg) and placebo.
  
  
  METHODS
  An outpatient clinic in an urban-based tertiary referral centre in the USA.
  
  
  METHODS
  Twenty-five outpatients meeting NINCDS criteria for probable Alzheimer's disease with associated behavioural disturbance.
  
  
  METHODS
  The Brief Psychiatric Rating Scale (BPRS), the Dementia Mood Assessment Scale (DMAS) and the Alzheimer Disease Assessment Scale (Cognitive) (ADAS-COG).
  
  
  RESULTS
  In the primary analysis, improvement on the BPRS and DMAS scores with selegeline treatment did not. reach statistical significance. A secondary analysis using a parallel design showed a significant benefit of drug treatment on BPRS scores with a trend towards improvement on the DMAS. Among the 10 subjects who could be tested, there was a significant improvement in cognitive function on the ADAS-COG with selegiline compared to placebo.
  
  
  CONCLUSIONS
  Short-term selegiline treatment produced an improvement in behaviour and had a significant effect on cognition in a subset of testable patients.
authors.affiliation: Department of Psychiatry, St James's Hospital, Dublin, Ireland.
authors.forename: B A
authors.initials: BA
authors.lastname: Lawlor
authors.forename: P S
authors.initials: PS
authors.lastname: Aisen
authors.forename: C
authors.initials: C
authors.lastname: Green
authors.forename: E
authors.initials: E
authors.lastname: Fine
authors.forename: J
authors.initials: J
authors.lastname: Schmeïdler
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D015577:Geriatric Assessment; D006801:Humans; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009483:Neuropsychological Tests; D011569:Psychiatric Status Rating Scales; D012642:Selegiline / Q000009:adverse effects / Q000627:therapeutic use*; D012920:Social Behavior Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology
chemical_list: D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline